Keros Therapeutics
KROS
51 hedge funds and large institutions have $410M invested in Keros Therapeutics in 2020 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
54.22% more ownership
Funds ownership: 0% → 54.22% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$57.8M |
| 2 |
OrbiMed
New York
|
+$51.7M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$44M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.9M |
| 5 |
VA
VR Adviser
New York
|
+$20.7M |
Top Sellers
KROS Hedge Fund Activity: Q2 2020 in Review
51 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q2 2020, worth a combined $410M.
Buyers outnumbered sellers: 51 funds opened new KROS positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $57.8M.
- 51 institutional investors held Keros Therapeutics (KROS) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $410M of Keros Therapeutics stock for Q2 2020.
- 51 funds opened new Keros Therapeutics positions in Q2 2020 and 0 closed out, a net change of +51 holders.
- The largest Keros Therapeutics buyer in Q2 2020 was RA Capital Management, an estimated $57.8M added.
Based on aggregated 13F filings for Q2 2020.